Zhi Tong Cai Jing·2025-10-15 02:19Core Viewpoint - Rongchang Biologics (09995) has seen a nearly 5% increase in stock price following the acceptance of its innovative drug, Taitasip, for the treatment of primary immunoglobulin A (IgA) nephropathy by the National Medical Products Administration (NMPA) of China, marking it as the first domestically developed new drug in this field [1] Group 1 - Rongchang Biologics' stock price rose by 4.75% to HKD 93.75, with a trading volume of HKD 226 million [1] - The drug Taitasip, a dual-target fusion protein, has been accepted for priority review by the NMPA, making it the first domestic original new drug submitted for IgA nephropathy [1] - VorBio, the overseas partner of Rongchang Biologics, appointed Dr. Navid Z.Khan as CMO, who has extensive experience in global drug development in the neurology and autoimmune fields [1] Group 2 - Huatai Securities expressed optimism about Taitasip's global development prospects, citing its strong competitive edge and potential in treating MG and being the first innovative drug reported in the pSS field [1] - The combination of Taitasip's innovative profile and Dr. Khan's experience is expected to enhance its global competitiveness [1]